Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Exclusion Criteria

• •Patient with de novo PLL;
• •Patient with secondary malignancy that will limit survival ≤5 years;
• •Patient with prior allogenic or autologous bone marrow transplant or peripheral blood stem cell transplant ≤12 months;
• •Patient receiving an investigational agent or an approved agent for an investigational purpose within last 4 weeks prior to study entry;
• •Patient with known history of glucose-6-phosphate dehydrogenase deficiency;
• •Patient with autoimmune hemolytic anemia;
• •Patient with known Central Nervous System involvement;
• •Patient with active, uncontrolled serious bacterial, viral or fungal infections
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.